Congress Explores Remedies For Corporate Tax Inversion “Fever”
This article was originally published in The Rose Sheet
Senate Finance Committee Chairman Wyden questions the suggestion that drug manufacturers’ corporate tax inversions lead to lower health-care costs in the U.S. Inversion transactions have been on the rise since Helen of Troy’s landmark reorganization in the early 1990s in Bermuda, with President Obama recently casting firms that move their businesses overseas for tax benefits as “corporate deserters.”
You may also be interested in...
OTC private label leader Perrigo acquires Irish firm Elan for $8.6 billion in a deal that will bring tax savings from being incorporated in Ireland, provide a stage for European expansion and tap into Elan’s royalty rights. “Simply stated, we're going to be able to further our international platform,” CEO Joseph Papa says.
OIG will focus on successful drugs that have been repurposed as orphans, noting nine of the 10 top selling drugs have both orphan and non-orphan indications.
To aid its value assessments, ICER is interested in helping FDA understand the importance of patient-relevant outcomes and consistent endpoints across trials of drugs for the same disease.